ATE353361T1 - Gezielten modifikation der chromatinstruktur - Google Patents

Gezielten modifikation der chromatinstruktur

Info

Publication number
ATE353361T1
ATE353361T1 AT01927467T AT01927467T ATE353361T1 AT E353361 T1 ATE353361 T1 AT E353361T1 AT 01927467 T AT01927467 T AT 01927467T AT 01927467 T AT01927467 T AT 01927467T AT E353361 T1 ATE353361 T1 AT E353361T1
Authority
AT
Austria
Prior art keywords
targeted modification
compositions
chromate
methods
chromate structure
Prior art date
Application number
AT01927467T
Other languages
English (en)
Inventor
Alan P Wolffe
Trevor Collingwood
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Application granted granted Critical
Publication of ATE353361T1 publication Critical patent/ATE353361T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ecology (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
AT01927467T 2000-04-28 2001-04-27 Gezielten modifikation der chromatinstruktur ATE353361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20059000P 2000-04-28 2000-04-28
US22852300P 2000-08-28 2000-08-28

Publications (1)

Publication Number Publication Date
ATE353361T1 true ATE353361T1 (de) 2007-02-15

Family

ID=26895902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927467T ATE353361T1 (de) 2000-04-28 2001-04-27 Gezielten modifikation der chromatinstruktur

Country Status (7)

Country Link
US (4) US7001768B2 (de)
EP (1) EP1276859B1 (de)
AT (1) ATE353361T1 (de)
AU (2) AU5391401A (de)
CA (1) CA2407460C (de)
DE (1) DE60126483T2 (de)
WO (1) WO2001083793A2 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104526A1 (en) * 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
CA2423620A1 (en) 2000-09-28 2002-04-04 Sangamo Biosciences, Inc. Nuclear reprogramming using iwsi and related chromatin remodeling atpases
US6919204B2 (en) 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
WO2002026960A2 (en) * 2000-09-29 2002-04-04 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
AU2884102A (en) * 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
JP2005503131A (ja) * 2001-05-11 2005-02-03 ザ バーナム インスティチュート Ｒｉｚに関するスクリーニング、診断および治療の方法
EP1402053A4 (de) * 2001-06-05 2005-05-11 Exelixis Inc Chds als modifikatoren des p53-wegs und verwendungsverfahren
US7264964B2 (en) * 2001-06-22 2007-09-04 Ceres, Inc. Chimeric histone acetyltransferase polypeptides
GB0117964D0 (en) * 2001-07-24 2001-09-19 Imp College Innovations Ltd Control of gene expression
CA2461290C (en) 2001-09-24 2014-11-25 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
US7553667B2 (en) 2002-06-06 2009-06-30 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Regulation of gene expression using chromatin remodelling factors
WO2003104462A2 (en) 2002-06-06 2003-12-18 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Regulation of gene expression using chromatin remodelling factors
AU2003295692A1 (en) * 2002-11-15 2004-06-15 Sangamo Biosciences, Inc. Methods and compositions for analysis of regulatory sequences
CA2508052A1 (en) * 2002-12-05 2004-06-17 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
WO2004085644A2 (en) * 2003-03-26 2004-10-07 Basf Plant Science Gmbh Method for producing recombinant organisms
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP2927318B1 (de) 2003-08-08 2020-05-20 Sangamo Therapeutics, Inc. Verfahren und Zusammensetzungen für gezielte Spaltung und Rekombination
WO2005028630A2 (en) 2003-09-19 2005-03-31 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US8133733B2 (en) * 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) * 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US7855824B2 (en) * 2004-03-06 2010-12-21 Qualcomm Mems Technologies, Inc. Method and system for color optimization in a display
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
EP2314614B1 (de) 2005-02-28 2015-11-25 Sangamo BioSciences, Inc. Anti-angiogene Verfahren und Zusammensetzungen
US8999943B2 (en) 2005-03-14 2015-04-07 Board Of Regents, The University Of Texas System Antigene oligomers inhibit transcription
EP2641970B1 (de) 2005-11-17 2014-12-24 Board of Regents, The University of Texas System Modulierung der Genexpression durch Oligomere, die auf chromosomale DNA ausgerichtet sind
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
GB0607063D0 (en) * 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
DK2049663T3 (en) 2006-08-11 2015-06-01 Dow Agrosciences Llc ZINC FINGER NUCLEASE-MEDIATED HOMOLOGOUS RECOMBINATION
CA2962856A1 (en) 2006-12-14 2008-06-26 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
US8563314B2 (en) * 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
CN101878307B (zh) 2007-09-27 2017-07-28 陶氏益农公司 以5‑烯醇式丙酮酰莽草酸‑3‑磷酸合酶基因为靶的改造锌指蛋白
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
EP2232569A2 (de) 2007-12-17 2010-09-29 QUALCOMM MEMS Technologies, Inc. PHOTOVOLTAIsche Elemente mit INTERFEROMETRIschen Rückseitenmasken
JP5456692B2 (ja) * 2007-12-20 2014-04-02 エシコン・インコーポレイテッド カプセル化された腎臓組織
AU2009256243A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
EP2206723A1 (de) 2009-01-12 2010-07-14 Bonas, Ulla Modulare DNA-bindende Domänen
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2393506B1 (de) * 2009-02-04 2018-03-28 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von nervenleiden
AU2010226313B2 (en) 2009-03-20 2014-10-09 Sangamo Therapeutics, Inc. Modification of CXCR4 using engineered zinc finger proteins
US8815586B2 (en) 2009-04-24 2014-08-26 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions
JP5866283B2 (ja) 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ， インコーポレイテッド トリヌクレオチド反復疾患を治療するための方法および組成物
AU2010308569B2 (en) 2009-10-22 2015-07-16 Corteva Agriscience Llc Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
PL2510096T5 (pl) 2009-12-10 2018-06-29 Regents Of The University Of Minnesota Modyfikacja DNA zależna od efektora TAL
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
CN103354715A (zh) 2011-01-14 2013-10-16 双刃基金会 具有针对柑橘溃疡病的抗性的柑橘树
AU2012333207A1 (en) * 2011-06-21 2014-01-23 E.I. Du Pont De Nemours And Company Methods and compositions for producing male sterile plants
WO2013009935A2 (en) 2011-07-12 2013-01-17 Two Blades Foundation Late blight resistance genes
AU2012284365B2 (en) 2011-07-15 2017-04-20 The General Hospital Corporation Methods of transcription activator like effector assembly
US10801017B2 (en) * 2011-11-30 2020-10-13 The Broad Institute, Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
BR112014018294B1 (pt) 2012-01-26 2022-01-11 Norfolk Plant Sciences, Ltd Método para produzir uma planta, cassete de expressão, e, célula bacteriana
AU2013217105B2 (en) * 2012-02-06 2018-02-01 Integrated Dna Technologies, Inc. Method of regulating CFTR expression and processing
JP6309461B2 (ja) * 2012-02-28 2018-04-11 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ ヒストンアセチル化の標的化
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
EP2841572B1 (de) 2012-04-27 2019-06-19 Duke University Genetische korrektur mutierter gene
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
WO2013184197A1 (en) 2012-06-07 2013-12-12 The Children's Hospital Of Philadelphia Controlled gene expression methods
EP2861737B1 (de) 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Gen-targeting in pflanzen durch dns-viren
EP3763810A3 (de) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T-zell-modifizierende verbindungen und verwendungen davon
EP3483185B1 (de) 2012-10-12 2020-09-09 The General Hospital Corporation Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
ES2894832T3 (es) 2012-11-01 2022-02-16 Cellectis Plantas para la producción de proteínas terapéuticas
EP2920319B1 (de) 2012-11-16 2020-02-19 Poseida Therapeutics, Inc. Ortsspezifische enzyme und verfahren zur verwendung
US20140178561A1 (en) 2012-12-21 2014-06-26 Cellectis Potatoes with reduced cold-induced sweetening
WO2014124284A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Tale transcriptional activators
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10113162B2 (en) 2013-03-15 2018-10-30 Cellectis Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
US9828582B2 (en) * 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
RU2693891C1 (ru) 2013-11-11 2019-07-05 Сангамо Байосайенсиз, Инк. Способы и композиции для лечения болезни хантингтона
US20170166920A1 (en) 2014-01-30 2017-06-15 Two Blades Foundation Plants with enhanced resistance to phytophthora
EP3119878B1 (de) 2014-03-18 2021-05-26 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur regulierung der zinkfingerproteinexpression
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
WO2015171603A1 (en) 2014-05-06 2015-11-12 Two Blades Foundation Methods for producing plants with enhanced resistance to oomycete pathogens
EP3158072B1 (de) 2014-06-20 2021-01-13 Cellectis Kartoffeln mit reduzierter granule-bound-starch-synthase
WO2016089920A1 (en) 2014-12-01 2016-06-09 The Broad Institute, Inc. Method for in situ determination of nucleic acid proximity
WO2016182881A1 (en) 2015-05-09 2016-11-17 Two Blades Foundation Late blight resistance gene from solanum americanum and methods of use
EP3929286A1 (de) 2015-06-17 2021-12-29 Poseida Therapeutics, Inc. Zusammensetzungen und verfahren zur führung von proteinen an spezifische loci im genom
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US10837024B2 (en) 2015-09-17 2020-11-17 Cellectis Modifying messenger RNA stability in plant transformations
WO2017062790A1 (en) 2015-10-09 2017-04-13 Two Blades Foundation Cold shock protein receptors and methods of use
EP3362571A4 (de) 2015-10-13 2019-07-10 Duke University Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
JP2018537112A (ja) 2015-12-18 2018-12-20 サンガモ セラピューティクス， インコーポレイテッド Ｍｈｃ細胞受容体の標的化破壊
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
UY37108A (es) 2016-02-02 2017-08-31 Cellectis Modificación de la composición de aceites de soja mediante el knockout dirigido de los genes fad3a/b/c
KR20220145913A (ko) 2016-08-24 2022-10-31 상가모 테라퓨틱스, 인코포레이티드 가공된 표적 특이적 뉴클레아제
JP7256739B2 (ja) 2016-09-07 2023-04-12 サンガモ セラピューティクス， インコーポレイテッド 肝臓遺伝子のモジュレーション
WO2018092072A1 (en) 2016-11-16 2018-05-24 Cellectis Methods for altering amino acid content in plants through frameshift mutations
CA3047121A1 (en) 2016-12-16 2018-06-21 Two Blades Foundation Late blight resistance genes and methods of use
WO2018198049A1 (en) 2017-04-25 2018-11-01 Cellectis Alfalfa with reduced lignin composition
AU2018256877B2 (en) 2017-04-28 2022-06-02 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018204469A2 (en) 2017-05-03 2018-11-08 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
WO2018209209A1 (en) 2017-05-12 2018-11-15 Two Blades Foundation Methods for screening proteins for pattern recognition receptor function in plant protoplasts
CN111542608A (zh) 2017-07-28 2020-08-14 双刃基金会 马铃薯y病毒抗性基因及使用方法
WO2019108619A1 (en) 2017-11-28 2019-06-06 Two Blades Foundation Methods and compositions for enhancing the disease resistance of plants
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
CN111954464A (zh) 2018-01-12 2020-11-17 双刃基金会 秆锈病抗性基因及使用方法
JP7332622B2 (ja) 2018-04-18 2023-08-23 サンガモ セラピューティクス， インコーポレイテッド ハンチンチン（ｈｔｔ）の調節のためのジンクフィンガータンパク質組成物
WO2019204766A1 (en) 2018-04-19 2019-10-24 The Regents Of The University Of California Compositions and methods for gene editing
EP3841204A4 (de) 2018-08-23 2022-05-18 Sangamo Therapeutics, Inc. Modifizierte zielspezifische basiseditoren
EP4234570A3 (de) 2018-09-18 2023-12-13 Sangamo Therapeutics, Inc. Für programmierten zelltod 1 (pd1) spezifische nukleasen
EP3908568B1 (de) 2019-01-11 2024-06-26 Acuitas Therapeutics, Inc. Lipide zur lipidnanopartikelfreisetzung von wirkstoffen
US20220251595A1 (en) 2019-06-27 2022-08-11 Two Blades Foundation Engineered atrlp23 pattern recognition receptors and methods of use
WO2021011348A1 (en) 2019-07-12 2021-01-21 The Regents Of The University Of California Plants with enhanced resistance to bacterial pathogens
AU2021308681A1 (en) 2020-07-16 2023-03-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
WO2022240931A1 (en) 2021-05-11 2022-11-17 Two Blades Foundation Methods for preparing a library of plant disease resistance genes for functional testing for disease resistance
CA3233676A1 (en) 2021-09-30 2023-04-06 The Sainsbury Laboratory Plant disease resistance genes against stem rust and methods of use
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
WO1997011972A1 (en) * 1995-09-28 1997-04-03 The Trustees Of Columbia University In The City Of New York Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
JP2850816B2 (ja) * 1995-12-18 1999-01-27 日本電気株式会社 バンプ接合検査装置及び検査方法
US6015709A (en) * 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5972608A (en) * 1997-08-27 1999-10-26 University Of Massachusetts Assays and reagents for chromatin remodeling enzymes and their modulators
US6153383A (en) * 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
AU746454B2 (en) * 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US20020188103A1 (en) * 1998-10-09 2002-12-12 Timothy H. Bestor Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
EP1276869A2 (de) 2000-01-21 2003-01-22 The Scripps Research Institute Methoden und zusammensetzungen zur expressionsmodulierung in pflanzen
KR20020086508A (ko) * 2000-02-08 2002-11-18 상가모 바이오사이언스 인코포레이티드 약물 발견용 세포
US7205103B2 (en) 2000-02-11 2007-04-17 The Salk Institute For Biological Studies Method of regulating transcription in a cell
WO2001068807A2 (en) 2000-03-16 2001-09-20 Fred Hutchinson Cancer Research Center Identification of in vivo dna binding loci of chromatin proteins using a tethered nucleotide modification enzyme

Also Published As

Publication number Publication date
CA2407460A1 (en) 2001-11-08
AU2001253914B2 (en) 2006-06-08
EP1276859A2 (de) 2003-01-22
US20090023153A1 (en) 2009-01-22
WO2001083793A2 (en) 2001-11-08
WO2001083793A3 (en) 2002-06-20
DE60126483D1 (de) 2007-03-22
DE60126483T2 (de) 2007-12-06
EP1276859B1 (de) 2007-02-07
US20060188972A1 (en) 2006-08-24
US20020115215A1 (en) 2002-08-22
US20100323424A1 (en) 2010-12-23
US7785792B2 (en) 2010-08-31
AU5391401A (en) 2001-11-12
US8071370B2 (en) 2011-12-06
US7001768B2 (en) 2006-02-21
CA2407460C (en) 2013-06-25

Similar Documents

Publication Publication Date Title
ATE353361T1 (de) Gezielten modifikation der chromatinstruktur
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
CY1117027T1 (el) Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων
SG150533A1 (en) 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
RS20050769A (en) Derivatives of 2-acylamino-4- phenylthiazole,preparation method thereof and application of same in therapeutics
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
WO2004062613A3 (en) Hiv integrase inhibitors
DE69837393D1 (de) Stimulierung von hämatopoietischen zellen im vitro
MXPA04000622A (es) Pirazolilcarboxanilidas como funguicidas.
WO2002013833A3 (en) SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2
MX2007010045A (es) Pirazolopirimidinas.
CY1108549T1 (el) Συνθετικες μεθοδοι για απλιδινη και νεα κατα του ογκου παραγωγα, μεθοδοι κατασκευης και χρησης αυτων
EA200300836A1 (ru) Производные фталазинон-пиперидина в качестве ингибиторов pde4
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
MXPA06002349A (es) Derivados de aminopropanol.
DE602004029602D1 (de) Brennstoffzelle, auseinanderbauverfahren dafür und darin verwendete trennglieder
DK1311670T3 (da) Fremgangsmåde til massiv dirigeret mutagenese
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
MY133969A (en) Indoloquinazolinones
HK1057336A1 (en) Pharmaceutical solutions of modafinil compounds
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
BRPI0500773A (pt) método para secagem de neotame com um co-agente para proporcionar um produto sólido contendo neotame, e, produto sólido contendo neotame possuindo uniformidade melhorada e estabilidade melhorada
MXPA06002919A (es) Sustancias colorantes azoicas dispersas.
RS20060206A (en) Aminopyridine-derivatives as inducible no-synthase inhibitors
WO2003065997A3 (en) Anti-infarction molecules

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties